Genmab's Antibody Franchise Enters a Post-Darzalex Era

Genmab A/S is a Copenhagen-headquartered biotechnology company focused on the discovery and development of antibody therapeutics, primarily in oncology. The company was founded in 1999 and has grown from a platform-licensing shop into a fully integrated biotech with clinical development, regulatory, and — increasingly — commercial capabilities.

How the company makes money:

• Royalty revenue — the largest historical contributor. Genmab licenses its antibody technology and co-develops assets with partners who fund late-stage development and commercialization, in exchange for tiered royalties on net sales. This is high-margin, low-operating-cost revenue.
• Collaboration and milestone revenue — upfront payments, development milestones, and regulatory milestones from partnership agreements. Lumpy and difficult to forecast quarter to quarter, but a meaningful source of non-dilutive funding.
• Product and license revenue — a smaller but strategically important line, reflecting Genmab's move toward retaining economics on selected programs.

Customers: Genmab's direct customers are its pharmaceutical partners, not patients or providers. End demand is driven by prescribing oncologists and, in many jurisdictions, by reimbursement bodies that determine access for high-cost oncology therapies. This means Genmab's revenue is two steps removed from the ultimate prescriber — a structural feature that limits its control over pricing and market access.

Scale: At a $24.1B market cap with 624.06M shares outstanding and $1.27 in EPS, Genmab sits in the large-cap biotech tier — large enough to fund multi-asset clinical development internally, small enough that a single successful wholly-owned program can move the equity materially. The 52-week range of $23.62 to $39.30 (a 66% spread) reflects a market that has not settled on a stable valuation framework for the transition story.

Near-term (next 4-8 quarters):

• Royalty base durability. The existing partnered antibody portfolio continues to generate royalty revenue, and the key near-term variable is whether underlying partner sales grow, plateau, or face generic/biosimilar erosion. Any erosion in the royalty base directly hits the highest-margin line in the P&L.
• Milestone cadence. Collaboration and milestone revenue is inherently lumpy. Quarters with regulatory or development milestones will show outsized revenue; quarters without will look soft. Investors should model this line on a multi-year average rather than extrapolating any single quarter.
• Pipeline readouts. Clinical data events are the primary near-term catalyst. Positive data on a wholly-owned or co-developed asset would validate the transition thesis and is the most likely trigger for multiple expansion.

Medium-term (3-5 years):

• Revenue mix shift. The central question is whether product and collaboration revenue grows to a share of total revenue that reduces dependence on any single royalty stream. Success here changes both the growth rate and the quality of that growth.
• Commercial infrastructure build-out. Retaining economics requires building commercial capabilities — medical affairs, market access, sales. This is a real opex investment that will pressure margins before it produces revenue, and the market will likely penalize the margin compression before it rewards the revenue.
• Platform expansion beyond oncology. Genmab's antibody engineering capabilities have applications in immunology and other therapeutic areas. Expansion here broadens the addressable market and reduces concentration in a single therapeutic category.

The growth trajectory is therefore not a smooth line. It is a series of step-functions tied to clinical and regulatory events, funded by a declining-but-durable royalty base. Investors should expect volatility in reported results that does not reflect underlying progress.

Note: Historical and projected line items beyond the verified current EPS of $1.27 are not available from the market data provided and are therefore left blank rather than estimated. The discussion below addresses the structural drivers of these lines.

What drives the numbers:

Genmab's revenue composition is the single most important analytical variable. Royalty revenue carries near-100% incremental margin — every additional dollar of partner sales flows almost entirely to operating income. Collaboration and milestone revenue is similarly high-margin but timing-dependent. Product revenue, as it scales, will carry cost of goods and commercial infrastructure costs that compress blended gross margin.

The consequence is that Genmab's reported gross margin will likely decline as the business successfully diversifies — a counterintuitive outcome where good strategic news looks like deteriorating financials. Analysts who anchor on margin expansion as the definition of progress will misread this transition.

R&D expense should be expected to grow in absolute terms as more programs advance into later-stage, more expensive trials. The offset is that a larger share of that R&D is now funded by Genmab's own balance sheet rather than a partner's — which is the point of the transition, but also the reason near-term earnings will be depressed relative to a pure-royalty model.

At $1.27 in EPS and $38.55 per share, the market is paying roughly 30x current earnings. That multiple is defensible only if the earnings base grows — which requires either royalty base expansion or successful conversion of pipeline assets into revenue.

Market size: The oncology therapeutics market is one of the largest and fastest-growing segments of the pharmaceutical industry, driven by aging demographics, expanded biomarker-based patient selection, and premium pricing for differentiated therapies. Antibody-based therapeutics — Genmab's core competency — represent a substantial and growing share of that market, particularly in hematologic malignancies and, increasingly, solid tumors.

Competitive positioning: Genmab's differentiation rests on its antibody engineering platforms, notably technologies that enhance immune effector function and enable bispecific antibody formats. These are technically demanding capabilities with a limited number of credible practitioners globally. Genmab's repeated ability to secure partnerships with large pharmaceutical companies is direct evidence that its platforms are viewed as differentiated rather than commoditized.

The weakness in the positioning is commercial, not scientific. Genmab has historically been the discovery engine, not the commercial owner, which means it has captured a minority of the value created by its own science. Closing that gap is the strategic imperative.

Named comparables:

• Regeneron Pharmaceuticals — a comparable in the sense that it combines a proprietary antibody platform with a mix of partnered and wholly-owned commercial assets; a useful benchmark for what a fully-integrated version of Genmab's model looks like.
• argenx — a smaller, more focused antibody company with wholly-owned commercial assets, illustrating the higher multiple the market assigns to retained economics.
• BioNTech — a platform-driven biotech with a mix of partnered and proprietary programs, comparable in the sense of being valued on pipeline optionality rather than current earnings.
• Amgen — a mature, large-cap antibody franchise, representing the terminal state of a successful antibody business and a useful anchor for what scale looks like.

DCF discussion: A discounted cash flow analysis for Genmab is unusually sensitive to two inputs: the terminal value assigned to the existing royalty base, and the probability-weighted value of pipeline assets. Because royalty revenue is high-margin and long-duration, the terminal value dominates the DCF output — which means the model is effectively a bet on the durability of partner sales rather than on near-term cash flows. Pipeline assets should be modeled as separate, probability-weighted cash flow streams with explicit success probabilities, not blended into a single growth rate. Given the absence of verified historical and projected financials beyond current EPS, a precise DCF output is not presented here; the framework matters more than the point estimate.

Comparable-company multiples:

Peer market caps and multiples are directional characterizations, not verified current figures.

The read-through: Genmab trades at a multiple consistent with a mature, single-stream royalty business, while carrying pipeline optionality and a platform that peers with retained economics are valued far more richly for. The gap between those two framings is the investment opportunity — and the risk, if the transition stalls.

• Royalty concentration risk. If a significant share of revenue derives from a small number of partnered products, any partner's commercial underperformance, competitive entry, or loss of exclusivity translates directly into a revenue and earnings hit with no offsetting lever.
• Partner-dependent outcomes. Genmab does not control commercialization, pricing, or lifecycle strategy for partnered assets. Partner strategic decisions — deprioritization, portfolio reallocation, or a change in development focus — can impair Genmab's economics without any action by Genmab itself.
• Clinical and regulatory binary risk. Pipeline assets are subject to trial failure and regulatory rejection. A late-stage failure on a program the market has capitalized into the valuation would likely produce a sharp, single-event drawdown.
• Margin compression during transition. Building commercial infrastructure and funding wholly-owned development depresses near-term margins and GAAP earnings. The market may punish the financial optics of the transition even if the strategic direction is correct.
• Competitive intensity in antibody therapeutics. Bispecifics and engineered antibodies are an increasingly crowded field, with large pharma and well-funded biotechs pursuing overlapping mechanisms. Differentiation that exists today may erode as competitors catch up.